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Abstract
Background: As a kind of versatility of cytokines, overexpression of macrophage migration inhibitory factor (MIF)
and vascular endothelial growth factor-C (VEGF-C) have been reported in a wide variety of tumors. However, the
correlation and mechanism between MIF and VEGF-C are still not clear. As an important signal transduction system,
MAPK signaling pathways participate in a variety of biological behavior of cells. The purposes of this study are to
study the relationship between MIF and VEGF-C and discuss the role of MAPK signal pathway in the relationship.
Methods: In this study, we first knocked down the MIF using small interfering RNA (siRNA) and built the stable low
expression MIF breast cancer cells (siRNA-MIF-MCF-7) and the negative control cells (siRNA-NC-MCF-7). And then,
we evaluated the expression of MIF using Western blot to confirm the effect of transfection. Using real-time
fluorescent quantitative polymerase chain reaction and enzyme-linked immunosorbent experiment, we respectively
examined the different expression of VEGF-C between siRNA-MIF-MCF-7 and siRNA-NC-MCF-7 and breast cancer
cells MCF-7. Moreover, we investigated the expression of p38 MAPK, P-p38 MAPK, p44/42 MAPK, and P-p44/42
MAPK in the three kinds of cells by Western blot to analyze the regulatory mechanism to VEGF-C.
Results: We found that MIF siRNA markedly reduced the expression of MIF. And the expression level of VEGF-C,
p38 MAPK, P-p38-MAPK, p44/42-MAPK, and P-p44/42 MAPK in siRNA-MIF-MCF-7 cells had different degree of
decrease compared with siRNA-NC-MCF-7 cells and MCF-7 cells.
Conclusions: These results suggest that MIF can regulate the expression of VEGF-C in breast cancer cells. And its
regulatory mechanism may work by activating the MAPK signaling pathway.
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Background
Breast cancer is one of the most common malignant tu-
mors in women, and its morbidity is still keeping rising.
However, the current treatment is still unsatisfactory.
Further research on breast cancer that involved in the
development of abnormal factors and its mechanism is
of great significance for antitumor therapy of breast
cancer. Macrophage migration inhibitory factor (MIF)
was first described as a product of activated lymphocytes
and named because of inhibiting the random movement
of cultured macrophages [1, 2]. As an inflammatory fac-
tor, a growing number of studies have shown that MIF is
involved in tumor occurrence and development. Overex-
pression of MIF was reported in numerous tumors such
as non-small cell lung cancer [3], gastric cancer [4],
breast cancer [5, 6], metastatic melanoma [7], and
neuroblastoma [8]. Tumor-associated angiogenesis is of
great significance to developing neoplasms. There has
been study shown that MIF is overexpressed in breast
cancer tissues, cells, and serum of patients. MIF expres-
sion level is correlated with the tumor microvessel dens-
ity, and patients with positive MIF expression show a
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worse disease-free survival [6]. Through activation of
MAP kinase, MIF enhances the vascular endothelial cell
growth and differentiation, promotes angiogenesis forma-
tion, and leads to support tumorigenesis finally [9, 10], but
the mechanism is still unclear.
Vascular endothelial growth factor-C (VEGF-C) is an
important family member of the vascular endothelial
growth factor. VEGF-C that binds to VEGFR-2 acceler-
ates the growth of vascular and lymphatic; VEGF-C and
VEGFR-3, which together have been reported can en-
hance the permeability of lymphatic vessels, promote
proliferation of lymphatic endothelial, and, in addition,
induce the lymphangiogenesis and expansion of lymph-
atic vessel [11]. VEGF-C has been detected in a large
variety of malignant human tumors, and the level of
expression is associated with lymph node metastasis
[12–14]. In particular, the high expression of VEGF-C/
VEGFR-3 in invasive breast carcinoma gives rise to
lymph node metastasis [15]. VEGF-C plays an indelible
role in stimulation the transport of tumor cells by
lymphatic vessels and angiogenesis. Although there are a
number of studies showing VEGF plays a significant role
in promoting the tumor cells growth and metastasis
because of the dual function of blood vessels and lymph-
atic vessels, the mechanism of how the tumor cells
stimulate the secretion of VEGF-C is still unclear.
Studies have reported that the expressions of MIF and
VEGF are strongly correlated [16]. In a certain range,
the exogenous increase of MIF concentration can cause
the increase of VEGF expression; furthermore, the pro-
duction of VEGF can be inhibited by neutralizing MIF
mAb [6, 8, 17]. Blocking the MIF receptor (CD74 and
CD44) using siRNA can also reduce the secretion of
VEGF [17]. Nevertheless, the mechanism of MIF on
VEGF is still unclear, and whether it has the same func-
tion on VEGF-C so as to influence the formation of
tumor lymphatic vessels remains unclear. In the present
study, we analyzed the expression of MIF in human
breast cancer cell line which was knocked down the MIF
messenger RNA (mRNA) using small interfering RNA
and expression changes of VEGF-C, p38-MAPK, P-
p38MAPK, p44/42-MAPK, and P-p44/42-MAPK to




Human breast cancer cell line (MCF-7) was originally
from Shanghai cell bank of the Chinese Academy of
Sciences (Shanghai, China). Gene Technology Co., Ltd
(Shanghai, China) was entrusted to build Lentiviral
vector. Reverse transcription reagent PrimeScript RT
Master Mix was purchased from TaKaRa (Kyoto, Japan).
Fluorescence quantitative PCR reagent Luminaris Color
HiGreen qPCR pre-mixed solution was purchased from
Thermo Scientific (Massachusetts, USA). GAPDH and
VEGF-C primers were designed and synthesized from
Invitrogen (Carlsbad, CA). VEGF-C quantitative enzyme-
linked immunosorbent experiment kit was purchased
from Siju biological material LTD (Suzhou, China). P38
MAPK, phospho-p38 MAPK, p44/42 MAPK, and
phospho-p44/42 MAPK monoclonal antibodies were pur-
chased from Cell Signaling Technology, Inc. (Boston,
USA). MIF rabbit monoclonal antibodies were purchased
from Abcam trading company LTD (Shanghai, China).
Cell culture
The experimental cells include the down-regulating ex-
pression of MIF cells (siRNA-MIF-MCF-7), negative
control cells (siRNA-NC-MCF-7), and blank control
cells (MCF-7). The down-regulating expression of MIF
cells are the MCF-7 of breast cancer cells which are
transfected by lentivirus carrying SiRNA. The negative
control cells are the breast cancer cells (MCF-7) which
are transfected by lentivirus without SiRNA. And un-
treated MCF-7 breast cancer cells served as the blank
control. All of the cells were cultured in RPMI 1640
containing 10 % heat-inactivated FBS, streptomycin
100 ng/mL, and penicillin 100 U/mL. Cultures were
maintained at 37 °C in a humidified incubator in an at-
mosphere of 95 % air plus 5 % CO2.
Real-time fluorescent quantitative polymerase chain
reaction
Total RNA of the three kinds of cells was extracted
using TRIzol according to the manufacturer’s protocol
and was reverse transcription reagent according to the
manufacturer’s instruction. The reaction system of real-
time fluorescent quantitative PCR included 10 μL SYBR,
1 μL sense primer, 1 μL antisense primer, 1 μL cDNA, and
7 μL dH2O. The samples were done in triplicate for the
target gene and internal control. The PCR primers were
designed as follows: VEGF-C, sense primer 5′-TGGCAA
CATAACAGAGAACAG-3′ and reverse primer 5′-AC
CAGGCTGGCAACTTCTAC-3′; GAPDH, sense primer
5′-AGGGGCCATCCATAAACAGTCTTC-3′ and reverse
primer 5′-AGAAGGCTGGGGCTCATTG-3′. Quantita-
tive test was carried out 40 cycles under the following
conditions: 95 °C for 3 min, 95 °C for 20 s, and 60 °C for
30 s. Calculating the average of each group of samples, the
relative transcript level of VEGF-C was analyzed by the
formula as follows: ΔCq = target gene Cq − reference gene
Cq; ΔΔCq = target gene ΔCq − standard values ΔCq; and
the relative copy of target gene = 2−△△Cq.
Enzyme-linked immunosorbent assay
VEGF-C ELISA was performed using a human ELISA
kit according to the methods recommended by the
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manufacturers. Every kind of cells was cultured for 48 h
in the medium before the supernatants of cells were col-
lected. The supernatants were centrifuged at 1000 rpm
for 10 min to remove the cells and debris and save in
freezer keeping in −20 °C.
Western blot analysis
Cells were seed in six-well plates and washed with
PBS before directly lysing in ×1 sample buffer. Pro-
teins were separated by 12 % sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred
electronically to PVDF membranes. Membranes were
blocked with TBST (Tris-buffer saline and 0.2 %
Tween-20) containing 5 % non-fat dry milk at room
temperature for 1 h and then incubated with anti-
MIF (1:4000 dilution) at room temperature for 2 h.
The membranes were incubated with the diluted pri-
mary antibodies including anti-p38 (1:1000 dilution),
anti-P-p38 (1:1000 dilution), anti-p44/42 (1:1000dilution),
and anti-P-p44/42(1:2000dilution) at 4 °C overnight. After
washed with TBST, they were incubated with anti-goat/
rabbit immunoglobulin G-horse radish peroxidase for 1 h
and then were washed again. The protein bands were de-
tected whether to be existed by enhanced chemilumines-
cence (ECL). GAPDH was used as the internal control.
Statistical analysis
SPSS 13.0 software was used to evaluate the statistical
difference of at least three independent experiments.
The differences between groups were analyzed by
two-tailed Student’s t test, with P < 0.05 considered
significant.
Results
Detection VEGF-C expression in the cells by real-time
fluorescent quantitative PCR
The data was analyzed using 2−△△C analysis method.
The result showed that the VEGF-C mRNA expres-
sion level in siRNA-MIF-MCF-7 cells was remarkable
reduced compared with that in siRNA-NC-MCF-7
cells (*P < 0.05). There was no statistically significant
difference of the expression of VEGF-C between
negative control siRNA-NC-MCF-7 cells and black
control MCF-7 cells. Calculated according to the ex-
pression of VEGF-C in MCF-7 cells was 100 %, the
mRNA expression of VEGF-C inhibition rate in
siRNA-MIF-MCF-7 cells was 53 %. Our date showed
that VEGF-C expression reduced after reducing MIF
expression in breast cancer cells MCF-7. The com-
parison between different cells is shown in Fig. 1.
Expression level of VEGF-C in supernatants of cells
Using ELISA, we assessed the VEGF-C secretion in
the culture supernatants. In the supernatants of
siRNA-MIF-MCF-7 cells, the average concentration
was 122 pg/mL. The average concentration of VEGF-C in
the supernatants of siRNA-NC-MCF-7 and MCF-7 cul-
tures was 341 and 342 pg/mL, respectively. As shown in
Fig. 2, the level of secreted VEGF-C protein in superna-
tants of the siRNA-MIF-MCF-7 cells was significantly
reduced comparing with siRNA-NC-MCF-7 cells and
MCF-7 cells (*P < 0.05). Taking VEGF-C expression level
of MCF-7 cells as standard, the expression of VEGF-C in-
hibition rate in siRNA-MIF-MCF-7 cells was 63 %. The
difference in supernatants VEGF-C between the siRNA-
NC-MCF-7 cells and MCF-7 cells was no statistically
significant.
Expression of MIF, p38-MAPK, P-p38-MAPK, p44/42-MAPK,
and P-p44/42-MAPK in cancer cells
Total protein of siRNA-MIF-MCF-7 cells, siRNA-NC-
MCF-7 cells, and MCF-7 cells was extracted after 7-day
transfection. To define the effects of MIF knockdown,
we first detected the expression of MIF using Western
blot. Our data showed that MIF siRNA significantly
inhibited MIF protein secretion. To further identify MIF
signaling pathway, expression and phosphorylation levels
of p38 and ERK1/2(p44/42) were detect by Western blot.
There results suggested that both ERK1/2 and p38
MAPK signaling pathways were inhibited relative to
siRNA-NC-MCF-7 cells and black control MCF-7 cells
after knockdown MIF expression (Fig. 3).
Fig. 1 VEGF-C mRNA expression measured by real-time fluorescent
quantitative PCR in siRNA-MIF-MCF-7 cells, siRNA-NC-MCF-7 cells, and
MCF-7 cells. GAPDH was used as the internal control. The differences
between groups were analyzed by two-tailed Student’s t test, with
*P < 0.05 considered significant. NS means there was no statistically
significant difference. The experiment was repeated three
times independently
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Discussion
MIF secreted by the tumor cells can promote the forma-
tion of new blood vessels and regulate the microenviron-
ment of tumor cells, so as to avoid immune surveillance
and promote the spread of tumor cells [18, 19]. How-
ever, it is still not clear about the way MIF playing a
wide range of biological function. In this study, we found
that the secretion level of VEGF-C decreased after we
knocked down MIF by detecting siRNA-MIF-MCF-7
cells, siRNA-NC-MCF-7 cells, and MCF-7 cells. In
addition, the expression and phosphorylation of p38-
MAPK and p44/42-MAPK decreased. These results
demonstrate that in breast cancer cells, the overexpres-
sion of MIF promotes the secretion of VEGF-C, and the
MAPK signaling pathway including p38 signaling path-
way and ERK1/2 signaling pathway are activated by in-
creasing the phosphorylation level of p38 and ERK1/2
(p44/42) and play a part in biological effects.
VEGF-C combined with VEGFR-3 plays an important
role in tumor growth and metastasis. As an important
member of the VEGF family, it reportedly induces not
only angiogenesis but also lymphangiogenesis. Increased
secretion of VEGF-C can promote the lymph node
metastasis of a variety of tumors, and it has a more
important significance for tumor growth and metasta-
sis [20, 21]. Studies have shown that VEGF-C overex-
pressed not only in intratumoral regions of breast
cancer tissue, its expression in peritumoral regions is
higher than that of cancerous tissue, thus promote the
formation of lymphatic vessels in the peritumoral areas.
This result in the formation of lymphatic vessels is im-
portant for tumor growth and metastasis [22, 23]. In hu-
man breast cancer cell line MDA-MB-231, IGF-1 can
regulate the secretion of VEGF-C by stimulating the
MAPK/ERR1/2 signaling pathway, and the application
of ERK1/2 inhibitors can block the effect of IGF-1 on
VEGF-C secretion [24]. Our study further confirmed
the conclusion that it can promote the exocytosis of
VEGF-C by activating MAPK signaling pathway. In
addition, the study also found that in breast cancer
cells, MIF regulates secretion of VEGF-C by influencing
stepwise phosphorylation of p38-MAPK and ERK1/2 two
classic MAPK signaling pathways. More exact mechanism
of the action and their effect of angiogenesis and lym-
phangiogenesis need further study.
Conclusions
In conclusion, taking MIF and the related signaling path-
way as therapeutic targets is striking. Although there are
Fig. 2 VEGF-C protein level measured by ELISA in the supernatants
of siRNA-MIF-MCF-7 cells, siRNA-NC-MCF-7 cells, and MCF-7 cells.
The differences between groups were analyzed by two-tailed
Student’s t test, with *P < 0.05 considered significant. NS means
there was no statistically significant difference. The experiment
was repeated three times independently
Fig. 3 Western blot analysis of MIF, p38-MAPK, P-p38-MAPK, p44/
42-MAPK, and P-p44/42-MAPK protein in siRNA-MIF-MCF-7 cells,
siRNA-NC-MCF-7 cells, and MCF-7 cells. GAPDH was used as the
internal control
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a lot of research, reports have revealed MIF takes an im-
portant role in cancer development, but the exact mech-
anism is still not clear, as a new tumor therapeutic target
is still full of challenges. The results from this study re-
veal that MIF stimulates the p38-MAPK signaling path-
way and ERK1/2 signaling pathway by enhancing the
phosphorylation of p38-MAPK and p44/42, meanwhile
promote VEGF-C extracellularly export. The discovery
provides new train of thought for the treatment of breast
cancer.
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